- Home
- AKA vs ANEB Comparison
AKA vs ANEB Comparison
Compare AKA & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- ANEB
- Stock Information
- Founded
- AKA 2018
- ANEB 2020
- Country
- AKA United States
- ANEB United States
- Employees
- AKA N/A
- ANEB N/A
- Industry
- AKA Catalog/Specialty Distribution
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- ANEB Health Care
- Exchange
- AKA Nasdaq
- ANEB Nasdaq
- Market Cap
- AKA 137.0M
- ANEB 111.8M
- IPO Year
- AKA 2021
- ANEB 2021
- Fundamental
- Price
- AKA $12.20
- ANEB $2.27
- Analyst Decision
- AKA Strong Buy
- ANEB Buy
- Analyst Count
- AKA 4
- ANEB 2
- Target Price
- AKA $25.75
- ANEB $8.00
- AVG Volume (30 Days)
- AKA 14.4K
- ANEB 13.6K
- Earning Date
- AKA 11-05-2025
- ANEB 11-13-2025
- Dividend Yield
- AKA N/A
- ANEB N/A
- EPS Growth
- AKA N/A
- ANEB N/A
- EPS
- AKA N/A
- ANEB N/A
- Revenue
- AKA $595,281,000.00
- ANEB N/A
- Revenue This Year
- AKA $7.08
- ANEB N/A
- Revenue Next Year
- AKA $4.31
- ANEB N/A
- P/E Ratio
- AKA N/A
- ANEB N/A
- Revenue Growth
- AKA 5.44
- ANEB N/A
- 52 Week Low
- AKA $7.00
- ANEB $0.80
- 52 Week High
- AKA $23.60
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- AKA 54.54
- ANEB 42.93
- Support Level
- AKA $11.52
- ANEB $2.21
- Resistance Level
- AKA $13.49
- ANEB $2.47
- Average True Range (ATR)
- AKA 1.07
- ANEB 0.09
- MACD
- AKA -0.08
- ANEB -0.02
- Stochastic Oscillator
- AKA 67.90
- ANEB 42.65
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.